Non-confidential partnering overview
A novel light-activatable payload for targeted oncology conjugates
GenLumina is developing a preclinical intracellular oncology payload platform that combines molecular tumor targeting with an independent second layer of selectivity: controlled spatial light activation.
Two layers of selectivity, one controllable payload
Molecular targeting determines where the therapeutic goes. Light provides an independent switch that determines where intracellular cytotoxic activity is activated.
Molecular targeting
An antibody, peptide or other ligand directs the GenLumina payload toward tumor cells.
Intracellular delivery
The ultra-small DNA-silver nanocluster payload is delivered into target cells and localizes intracellularly.
Spatial activation
Controlled local light activates the payload within the selected treatment field.
Selective killing
Activation triggers localized cytotoxic activity designed to eliminate tumor cells while limiting off-target activation.
Target biology determines where the payload goes. Light determines where it becomes active.
Proof-of-concept established; partner-specific validation is the next step
GenLumina has demonstrated targeted/conjugated in-vitro activity in breast and colorectal cancer models. The proposed Novartis study would evaluate the platform with Novartis-selected targeting biology.
Demonstrated
- Light-activated intracellular cytotoxic payload concept
- Targeted/conjugated in-vitro proof-of-concept
- Activity in breast cancer models
- Activity in colorectal cancer models
- Modular antibody- and peptide-targeting concept
Partner-specific validation
- Conjugation with a Novartis-selected antibody or ligand
- Cellular uptake and intracellular localization
- Controlled light activation and tumor-cell killing
- Selectivity / therapeutic-window assessment
- Progression to in-vivo proof-of-concept if predefined criteria are met
A potential fit with targeted delivery and next-generation oncology payload innovation
This section is deliberately partner-specific. The rest of the page follows the standard GenLumina partnering format.
Novartis publicly lists breast, colorectal, pancreatic, prostate and lung cancers among current oncology partnering focus areas.
Novartis publicly identifies targeted delivery, selective tropism, biodistribution and intracellular trafficking within its biotherapeutics partnering interests.
Novartis' July 2026 agreement to acquire Myricx Bio is centered on a differentiated ADC payload platform and next-generation targeted drug conjugates.
A focused experiment rather than a broad licensing discussion
The initial objective is to determine whether GenLumina's payload architecture merits further evaluation with a Novartis-selected targeting molecule.
Can a Novartis-selected tumor-targeting antibody or ligand be combined with the GenLumina payload to create a differentiated, spatially controllable therapeutic architecture?
Suggested work package
- Define the Novartis-selected targeting molecule and conjugation strategy
- Assess conjugation feasibility and stability
- Measure cellular uptake and intracellular localization
- Evaluate controlled light activation, tumor-cell killing and selectivity
- Progress to in-vivo proof-of-concept if predefined criteria are met
Explore a Novartis × GenLumina feasibility study
We would welcome an initial non-confidential scientific and partnering discussion to determine whether the platform is relevant to Novartis Oncology.